Journal Logo

Advanced Search

Video Gallery

Clinical Trials of Interest

Video Author: Oncology Times
Published on: 08.02.2018

Pierluigi Porcu, MD, Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at the Sidney Kimmel Cancer Center at Jefferson Health, discusses a few hematology/oncology clinical trials in which he and his team are involved.

Related Videos

All Videos
Most Viewed
Most Emailed



Clinical Trials of Interest
Creator: Oncology Times
Duration: 2:43
Pierluigi Porcu, MD, Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at the Sidney Kimmel Cancer Center at Jefferson Health, discusses a few hematology/oncology clinical trials in which he and his team are involved.
Play Video | + Favorites
Why I Became an Oncologist
Creator: Convention News Television
Duration: 3:20
Oncologists across disciplines share their passion for the profession and discuss why they chose a career in cancer care.
Play Video | + Favorites
Why I Became an Oncologist: Dean H. Gesme, MD, FASCO, FACP
Creator: Convention News Television
Duration: 1:08
Dean H. Gesme, MD, FASCO, FACP, MD, from Minnesota Oncology, shares his passion for cancer care and the rewards of oncology practice.
Play Video | + Favorites
Why I Became an Oncologist: A. Craig Lockhart, MD
Creator: Convention News Television
Duration: 0:46
A. Craig Lockhart, MD, from Sylvester Comprehensive Cancer Center, became an oncologist to improve the standard-of-care and make a difference in the lives of cancer patients.
Play Video | + Favorites
Why I Became an Oncologist: Ramaswamy Govindan, MD
Creator: Convention News Television
Duration: 1:28
Ramaswamy Govindan, MD, from the Washington University School of Medicine, St. Louis, Mo., discusses the breakthroughs he has witnessed in cancer research and treatment as well as why this is an exciting time to be an oncologist.
Play Video | + Favorites
Why I Became an Oncologist: Paul Bunn, MD, FASCO
Creator: Convention News Television
Duration: 1:02
Paul Bunn, MD, FASCO, of the University of Colorado Cancer Center, discusses why he became an oncologist as well as his passion for research and patient care.
Play Video | + Favorites
Why I Became an Oncologist: Stephen D. Nimer, MD
Creator: Convention News Television
Duration: 0:43
Find out why Stephen D. Nimer, MD, of Sylvester Comprehensive Cancer Center, chose to pursue a career in oncology.
Play Video | + Favorites
Why I Became an Oncologist: Ishwaria M. Subbiah, MD, MS
Creator: Convention News Television
Duration: 1:20
Ishwaria M. Subbiah, MD, MS, of the University of Texas MD Anderson Cancer Center, Houston, shares her passion for oncology and quality patient care.
Play Video | + Favorites
Good Results with Accelerated Partial Breast Irradiation for Older Women with Early Breast Cancer
Creator: Sarah Maxwell
Duration: 4:22
Icro Meattini, MD, Consultant Clinical Oncologist at the University of Florence, discusses a subgroup analysis of a Phase III randomized study of women with early breast cancer, which he presented at the 2015 European Society for Radiotherapy & Oncology Forum in Barcelona.
Play Video | + Favorites
Immunotherapy Updates in Melanoma and More from the 2013 International Meeting of the Society for Melanoma Research
Creator: Dan Keller
Duration: 5:41
Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses topics from a session on immunotherapy of melanoma at the International Meeting of the Society for Melanoma Research, and he summarizes presentations on the need for biomarkers for patient selection and as potential therapeutic targets themselves, the utility of immunotherapy plus radiation, and stimulation of antigen-presenting cells.
Play Video | + Favorites
T-DM1 Shown to Double PFS in HER2-Pos Advanced Refractory Breast Cancer
Creator: Sarah Maxwell
Duration: 1:44
Professor Hans Wildiers, MD, PhD, from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, explains why TDM-1 doubles progression-free survival in HER2-positive advanced refractory breast cancer.
Play Video | + Favorites
Idelalisib for CLL
Creator: Dan Keller
Duration: 5:39
Richard Furman, MD, discusses the Phase III trial of idelalisib, a first-in-class oral kinase inhibitor and highly selective inhibitor of the delta isoform of PI3 kinase, used in combination with rituximab. The data show better progression-free survival and objective response rates compared with rituximab plus placebo in CLL patients who had already received standard treatments and were not considered candidates for additional chemotherapy.
Play Video | + Favorites
Reduced-Intensity Conditioning Shown to Spare Cognitive Function
Creator: Dan Keller
Duration: 5:29
Smita Bhatia, MD, MPH, elaborates on the clinical implications of her research.
Play Video | + Favorites
Colorectal Cancer Screening Survey Finds Big Mortality Benefit for Europe
Creator: Peter Goodwin
Duration: 1:50
Changes in colorectal cancer mortality are found to be correlated with the level of screening uptake—providing a strong rationale for national bowel cancer screening programs, this researcher explains.
Play Video | + Favorites
Jedd Wolchok on the Next Big Steps for Melanoma Treatment
Creator: Dan Keller
Duration: 5:20
Jedd Wolchok, MD, elaborates on his presentation at the 10th International Meeting of the Society for Melanoma Research about the need for therapies for melanoma beyond current CTLA-4 blockade, findings on biomarkers for response, PD-L1 expression as a biomarker on tumor cells, and the potential for targeted combination treatments.
Play Video | + Favorites
Intraoperative RT with Lumpectomy as Effective & Safer than WBI
Creator: Peter Goodwin
Duration: 2:10
TARGIT-A investigators Jayant S. Vaidya, PhD, and Michael Baum, MB, ChB, FRCS, elaborate on their findings and the clinical implications.
Play Video | + Favorites
Obinutuzumab Beating Rituximab for CLL
Creator: Dan Keller
Duration: 6:51
Valentin Goede, MD, elaborates on the clinical implications of the “paradigm-changing” CLL11 Phase III study that found improved responses for patients with chronic lymphocytic leukemia receiving obinutuzumab-chlorambucil compared with those receiving rituximab-chlorambucil.
Play Video | + Favorites
Cancers of Unknown Primary Site: Biomarker Profiling Enables Shift in Treatment Approach
Creator: Sarah Maxwell
Duration: 2:39
Zoran Gatalica, MD, DSc, Executive Medical Director of Caris Life Sciences in Phoenix, Arizona, discusses his study of 1,400 patients with cancers of unknown primary site in whom 80 percent were found to have actionable molecular targets in a video interview at the European Cancer Congress.
Play Video | + Favorites
Advanced, Unresectable Melanoma: Pooled Analysis Finds Long-Term Survival ‘Plateau’
Creator: Peter Goodwin
Duration: 2:18
Michele Maio, MD, PhD, Director of Medical Oncology & Immunotherapy at University Hosptial in Siena, Italy, and Keith Flaherty, MD, Director of the Termeer Center for Targeted Therapies at Massachusetts General Hospital, discuss the findings that they presented at the 2013 European Cancer Congress.
Play Video | + Favorites
Diabetes Appears to Increase Risk, Mortality of Breast and Colon Cancers
Creator: Peter Goodwin
Duration: 1:36
Kirstin De Bruijn, a doctoral student in the surgery department at Erasmus University Medical Center in Rotterdam, the Netherlands, discusses her findings about the links between diabetes and breast and colorectal cancers, which she presented at the 2013 European Cancer Congress.
Play Video | + Favorites



New Immunotherapeutic Approaches
Creator: Dan Keller
Duration: 4:51
Show More 
Show Less 
Roy Herbst, MD, PhD, Professor of Medicine and Pharmacology and Chief of Medical Oncology at Yale Cancer Center, discusses a promising new technique that overcomes the inability of T cells to attack cancer.
Play Video | + Favorites